Physician profile
Daniel K Howard
NPI 1962422212
$1,571.01
in general payments reported to CMS, 2019-2025
16 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $328 · 2021: $169 · 2022: $208 · 2023: $161 · 2024: $117 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.56 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $221.45 | 2020-2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Insmed, INC. | $218.35 | 2020-2025 | |
| United Therapeutics Corporation | $213.76 | 2025 | Tyvaso |
| Chiesi USA, INC. | $192.18 | 2019-2022 | |
| Grifols USA, LLC | $189.78 | 2020-2023 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $123.83 | 2019 | |
| Galvanize Therapeutics, INC | $109.09 | 2023 | Aliya System |
| Intuitive Surgical, INC. | $104.91 | 2019 | |
| Advanced Respiratory, INC | $49.06 | 2021 | |
| Glaxosmithkline, LLC. | $47.73 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Regeneron Healthcare Solutions, INC. | $25.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.35 | 2021 | |
| Tactile Systems Technology INC | $17.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2021 | |
| Mylan Specialty L.P. | $11.68 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.